David R. Bauer
      Lawyers
    
     
Filters
Novo Nordisk proposed $9.1 billion acquisition of Metsera
        We are advising Novo Nordisk on the transaction
      
      GSK exclusive license agreement with Empirico
        We advised GSK on the transaction
      
      RAPT Therapeutics $250 million follow-on offering
        The shares are listed on the Nasdaq Global Market
      
      Nurix Therapeutics $250 million stock offering
        The stock is listed on the Nasdaq Global Market
      
      Esperion Therapeutics follow-on offering
        The shares are listed on Nasdaq
      
      Turn Therapeutics direct listing
        We advised Turn Therapeutics on its Nasdaq listing
      
      Neptune $368 million IPO
        The shares are listed on the New York Stock Exchange
      
      Amulet Capital Partners sale of SSI Strategy to Clinigen
        We are advising Amulet Capital Partners and SSI Strategy on the sale
      
      Medtronic €1.5 billion notes offering
        The investment-grade notes are due 2030 and 2045
      
      MBX Biosciences $200 million follow-on offering
        The shares are listed on the Nasdaq Global Select Market